NCT04894110 - Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

October 3, 2024

Study Completion Date

October 3, 2024

Conditions

Corneal EdemaCorneal Endothelial DysfunctionCorneal Endothelial DystrophyFuchs DystrophyFuchs Endothelial Corneal DystrophyPseudophakic Bullous KeratopathyBullous KeratopathyEndothelial DysfunctionModerate Corneal Endothelial Decompensation

Interventions

BIOLOGICAL

EO2002

EO2002 (magnetic human corneal endothelial cells \[HCECs\]) with and without endothelial brushing (EB) or Descemet Stripping (DS)

BIOLOGICAL

EO2002 low dose

Low dose of EO2002 (magnetic human corneal endothelial cells)

BIOLOGICAL

EO2002 mid dose

Mid dose of EO2002 (magnetic human corneal endothelial cells)

BIOLOGICAL

EO2002 high dose

High dose of EO2002 (magnetic human corneal endothelial cells)

Trial Locations (8)

30339

Atlanta Location, Atlanta

33136

Miami Location, Miami

33410

Palm Beach Gardens Location, Palm Beach Gardens

49546

Grand Rapids Location, Grand Rapids

50266

Des Moines Location, Des Moines

66204

Kansas City Location, Overland Park

91208

Los Angeles Location, Greater Los Angeles

92122

San Diego Location, San Diego